PHMMF Stock Chart & Stats
$96.00
$0.00(0.00%)
At close: 4:00 PM EDT
$96.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$72.65 - $114.26
Previous CloseN/A
Volume41.00
Average Volume (3M)15.00
Market Cap
$1.34B
Enterprise Value$1.18B
Total Cash (Recent Filing)$168.88M
Total Debt (Recent Filing)$45.84M
Price to Earnings (P/E)20.7
Beta0.58
Next Earnings
Mar 01, 2027EPS Estimate
1.1Next Dividend Ex-DateN/A
Dividend Yield1.52%
Share Statistics
EPS (TTM)3.26
Shares Outstanding18,000,000
10 Day Avg. Volume46
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.12
Price to Sales (P/S)5.82
P/FCF Ratio29.46
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue5.42
Enterprise Value/Gross Profit5.98
Enterprise Value/Ebitda27.50
Forecast
1Y Price Target
$112.06Price Target Upside16.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.03
Revenue Forecast (FY)$235.49M
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsVery high gross and net margins indicate that Pharma Mar’s oncology portfolio generates substantial economic value relative to sales. If maintained, this profitability can fund research, commercialization, and partnerships while providing resilience against moderate operating volatility over the coming quarters.
Conservative Balance SheetLow leverage and a solid equity base reduce the company’s dependence on external financing and limit interest-related pressure. This gives Pharma Mar greater flexibility to support oncology development, absorb earnings variability, and pursue opportunities without materially weakening financial stability.
Recent Positive Cash ConversionRecent operating and free cash flow demonstrate that reported earnings are translating into cash at a generally healthy rate. Strong conversion improves the company’s ability to fund operations and research internally, reducing reliance on debt or equity while supporting business durability.
Bears Say
Inconsistent Revenue GrowthThe latest revenue decline shows that Pharma Mar’s top-line performance is not consistently expanding despite the company’s strong profitability. Uneven sales growth can limit operating leverage, make investment planning less predictable, and increase dependence on product or partnership performance.
Volatile Free Cash FlowAlthough recent cash generation is positive, the history of negative free cash flow and the latest year-over-year decline show meaningful variability. Such fluctuations can constrain the timing of research investment and make internally funded growth less dependable across business cycles.
Uneven Earnings PerformanceThe sharp swings in EBIT and net income indicate that profitability has not yet demonstrated a consistently stable trajectory. Earnings sensitivity can complicate forecasting, reduce confidence in recurring profit power, and make future returns more dependent on operating conditions and portfolio execution.
Pharma Mar SA News
PHMMF FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was $72.65 and its highest was $114.26 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is $1.34B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Mar 01, 2027 which is in 120 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Oct 29, 2026. The company reported $0.527 earnings per share for the quarter, beating the consensus estimate of $0.142 by $0.384.
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA pays a Annually dividend of $1.139 which represents an annual dividend yield of 1.52%. See more information on Pharma Mar SA dividends here
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 1.1.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of $0.527 in its last earnings report, beating expectations of $0.142. Following the earnings report the stock price went down -0.837%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in PHMMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharma Mar SA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$112.06 (16.73% Upside)
$112.06 (16.73% Upside)
Blogger Sentiment
Neutral
PHMMF Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth $37.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.27%
12-Months-Change
Fundamentals
Return on Equity
23.64%
Trailing 12-Months
Asset Growth
10.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
PHMMF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all PHMMF earnings summariesPHMMF Stock 12 Month Forecast
Average Price Target
$112.06
▲(16.73% Upside)
Technical Analysis
Laboratorios Farmaceuticos Rovi
―
Oryzon Genomics SA
―
―
1nKemia IUCT Group SA
―
Atrys Health SA
―
Ownership Overview
― Insiders
3.35% Mutual Funds
― Other Institutional Investors
91.52% Public Companies and
Individual Investors